Serum level of YKL-40 does not predict advanced liver fibrosis in children with chronic hepatitis B.
The aim of the study was to evaluate the serum concentration of YKL-40 (human cartilage glycoprotein-39) in the assessment of fibrosis stage in children compared to biopsy and prior to antiviral treatment for chronic hepatitis B. We determined serum level of YKL-40 (METRA, EIA kit, Quidel Corporation, San Diego, USA) after an overnight fast in 63 children (age range 4-17 years, mean 10 years) with biopsy-verified chronic HBeAg-positive hepatitis B. Fibrosis stage and inflammation grade were assessed in a blinded fashion according to Ishak et al. We defined advanced liver fibrosis as a score >2. Receiver operating characteristics (ROC) analysis was used to calculate the power of the assay to detect advanced liver fibrosis (AccuROC, Canada). Serum concentration of YKL-40 was significantly higher in patients with chronic hepatitis B compared to controls (n=16) (38.5 +/- 19.2 vs 27.9 +/- 8.75 ng/mL; p = 0.032). The ability of serum YKL-40 to differentiate children with advanced liver fibrosis (n=31; 49.2%) from those with mild fibrosis was not significant (AUC = 0.387 +/- 0.072, p = 0.12). This marker was not a good predictor of histologic inflammation either. Serum level of YKL-40 does not predict advanced liver fibrosis in children with chronic hepatitis B.